Combination of Oxaliplatin and Vit.E-TPGS in Lipid Nanosystem for Enhanced Therapeutic Efficacy in Colon Cancers

Wang, Yanlei; Zhang, Xiang; Zhang, Wenqiang; Dong, Huijuan; Zhang, Wenjie; Mao, Jiajia; Dai, Yong

doi:10.1007/s11095-017-2297-x

Cited by 7 publications

(4 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As beta-carotene and as a retinoid, Dl alpha tocopheryl (Vit E) acts as an anti-oxidant [34] and exerts anti-tumoral action, thus contrasting tumor growth [35,36,37]. Moreover, the anti-tumoral action of Dl alpha tocopheryl is synergistic with that of some common antiblastics [38,39,40]. The below reported IT schedule is consistent with these experimental and clinical findings.…”

Section: Six Cases Reports and Methodssupporting

confidence: 71%

Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports

Nicolini

Morganti

Carpi

2019

IJMS

View full text Add to dashboard Cite

This article summarizes the histories of six patients with different solid tumors treated with a new strategy based on tumor burden reduction and immune evasion as potential targets. All six patients were at a high risk of relapse and were likely to have a minimal residual disease following conventional therapy: biochemical recurrence (BCR) following radical prostatectomy (RP) (two prostate cancers patients), removal of distant metastases (one colorectal and one breast cancer), and complete response (CR) of distant metastases to conventional therapy (one breast cancer and one esophageal–gastric junction cancer). Four of the patients, two after RP and BCR, one after removal of a single pulmonary metastasis from breast cancer, and one after CR to chemotherapy of peritoneal metastases and ascites from an esophageal–gastric junction primary cancer, regularly received cycles of a new drug schedule with the aim of inhibiting immune suppression (IT). In these four patients, preliminary laboratory tests of peripheral blood suggested an interleukin (IL)-2/IL-12 mediated stimulation of cellular immune response with a concomitant decrease in vascular endothelial growth factor (VEGF) immune suppression. The fifth case was a breast cancer patient with distant metastases in CR, while receiving beta-interferon and interleukin-2 in addition to conventional hormone therapy. To date, all five patients are alive and doing well and they have been unexpectedly disease-free for 201 and 78 months following BCR, 28 months following the removal of a single pulmonary metastases, 32 months following CR to chemotherapy of peritoneal metastases and ascites, and 140 months following diagnosis of multiple bone metastases, respectively. The sixth patient, who had colorectal cancer and multiple synchronous liver metastases and underwent nine surgical interventions for metastatic disease, although not disease-free, is doing well 98 months after primary surgery. Our six cases reports can be interpreted with the hypothesis that immune manipulation and/or a concomitant low tumor burden favored their clinical outcome.

show abstract

Section: Six Cases Reports and Methodssupporting

confidence: 71%

Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports

Nicolini

Morganti

Carpi

2019

IJMS

View full text Add to dashboard Cite

show abstract

“…The enhanced anticancer impact of OXL based on nanoparticles is demonstrated by the 3-fold lower IC50 value of OLX/TLNP. The findings signify the importance of TPGS in cancer research ( 27 ). When creating drug delivery systems, D-alpha-tocopheryl polyethylene glycol succinate (TPGS) is widely utilised to enhance the pharmacokinetics of anti-cancer medications and lower multi-drug resistance ( 28 ).…”

Section: Introductionmentioning

confidence: 56%

“…In order to combat the lymphatic metastasis of colorectal cancer, the current study sought to engineer D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS) nanoscale Sorafenib tosylate (ST) loaded lipid-based as LDDS of ST ( 26 ). To increase the anticancer effect in colon cancer cells, Yanlei Wang et al ( 27 ) created oxaliplatin (OXL)-loaded D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS) based lipid nanoparticles. The anticancer impact of OXL was noticeably enhanced in HT-29 colon cancer cells by the presence of TPGS.…”

Section: Introductionmentioning

confidence: 99%

Development of D-α-Tocopherol polyethylene glycol 1000 succinate fabricated nanostructural lipid carrier of sorafenib tosylate for metastatic colorectal targeting application: Stability, physical characterization, cytotoxicity, and apoptotic studies against SW48 cells PTEN

2022

View full text Add to dashboard Cite

The study aimed to create D-α-Tocopherol polyethylene glycol 1000 succinate (TPGS) nanostructured lipid carriers (NLC) of sorafenib tosylate (ST) as lymphatic delivery systems (LDDS) to fight Metastatic colorectal cancer. Initially, ST-SLN, ST-NLC, and ST-LNE were formulated considering oleic acid (OA), glycerol monolinoleate (GMO), glycerol monolinoleate (GML) as solid lipid and further characterised, and tested for stability. The most stable ST-NLC was fabricated with TPGS to produce ST-TPGS-NLC and evaluated by performing in vitro drug profiling, in vitro cytotoxicity, and apoptotic studies against human female colorectal adenocarcinoma cell lines (SW48 Cells PTEN). Stability studies on three lipidic nanoparticles (ST-SLN, ST-NLC, ST-LEN) showed particle size, polydispersity index, and zeta potential ranging from 165 nm to 298 nm, 0.125 to 0.288, and -31 mV to -16 mV. At 1600 minutes, more than 80% of ST-NLC1 was released, confirming the sustained release pattern of the formulation. ST-NLC and ST-TPGS-NLC have entrapment efficiencies above 50%. Pure ST’s IC50 at 72 hr was 3.45 µg/mL, while 1.56 µg/mL was for ST-TPGS-NLC. The ST-TPGS-NLC reduced the number of livings SW48 Cells PTEN from 91% to 5%, compared to 75% to 8% of pure ST. The ST-TPGS-NLC is a promising LDDS for delivering ST for metastatic colorectal cancer.

show abstract

“…The IC 50 value of the formulation was 1.12 μg/mL compared to the free drug (4.25 μg/mL). The formulation induced significant apoptosis of the cancer cells with 52% early apoptosis phase and 13% late apoptosis phase [ 122 ]. Luiza et al evaluated the anticancer efficacy of retinoic acid and oxaliplatin loaded into cholesterol-coated Poly ( D , L -lactide-co-glycolic acid) NPs for effective encapsulation and administration [ 123 ].…”

Section: Nanoparticles Loaded With Platinum Drugs For Colorectal Canc...mentioning

confidence: 99%

Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy

Buyana

Naki

Alven

et al. 2022

IJMS

View full text Add to dashboard Cite

Colorectal cancer is a common cancer in both men and women. Numerous studies on the therapeutic effectiveness of nanoparticles against colorectal cancer have been reported. Platinum treatments as well as other medications comprising of nanoparticles have been utilized. Drug resistance restricts the use of platinum medicines, despite their considerable efficacy against a variety of cancers. This review reports clinically licensed platinum medicines (cisplatin, carboplatin, and oxaliplatin) combined with various nanoparticles that have been evaluated for their therapeutic efficacy in the treatment of colorectal cancer, including their mechanism of action, resistance, and limitations.

show abstract

Combination of Oxaliplatin and Vit.E-TPGS in Lipid Nanosystem for Enhanced Therapeutic Efficacy in Colon Cancers

Cited by 7 publications

References 22 publications

Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports

Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports

Development of D-α-Tocopherol polyethylene glycol 1000 succinate fabricated nanostructural lipid carrier of sorafenib tosylate for metastatic colorectal targeting application: Stability, physical characterization, cytotoxicity, and apoptotic studies against SW48 cells PTEN

Nanoparticles Loaded with Platinum Drugs for Colorectal Cancer Therapy

Contact Info

Product

Resources

About